Critical pertussis infection in the paediatric intensive care unit: A case series in an outbreak
Article Sidebar
Main Article Content
Abstract
Background. Bordetella pertussis is a highly infectious disease associated with increased mortality in young infants. Critical pertussis is defined as pertussis disease resulting in paediatric intensive care unit admission or death.
Objective. This study describes the clinical profile, morbidity, mortality and management of children with critical pertussis admitted to a South African paediatric intensive care unit (PICU).
Study design. A retrospective analysis of children with critical pertussis admitted to the PICU over 1 year (January 2022 - December 2022).
Results. There were 1 273 PICU admissions during the study period, of which 101 (7.9%) were tested and 19 (1.5%) tested positive for B. pertussis. Of those, 13 (68.4%) were completely unimmunised, mainly owing to young age (n=9). The median (interquartile range) total duration of ventilation was 7.0 (3.0 - 21.0) days, with a maximum of 35 days. Mortality was 36.8% (n=7) in those with B. pertussis; with more deaths in HIV-exposed patients (n=3/7,42.9% v. n=3/12, 25%; p<0.001) and preterm infants (n=4/7,57.1% v. n=4/12, 33.3%; p<0.001), as well as those with septic shock (n=7/7, 100% v. n=4/7, 33.3%; p = 0.02) and acute kidney injury (n=6/7, 85.7% v. n=2/12, 16.7%; p<0.001). The maximum white cell count was significantly lower in survivors (27.75 v. 76.32; p<0.001). None of the variables was independently associated with mortality on multivariable regression.
Conclusion. Critical B. pertussis infection is associated with significant morbidity and mortality in this setting. The low rate of vaccination is a concern, and advocacy is needed to promote access to vaccination during the third trimester of pregnancy as well as strengthening current immunisation programmes. Further research is required to identify the prevalence of critical pertussis and risk factors for poor outcomes in resource-limited settings.
Article Details
Issue
Section
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The SAJCC is published under an Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
How to Cite
References
1. Muloiwa R, Wolter N, Mupere E, et al. Pertussis in Africa: findings and recommendations of the Global Pertussis Initiative (GPI). Vaccine 2018;36(18):2385-2393.
2. NICD. Increase in pertussis cases in South Africa (21 Sept 2022). 2022; Available from https:// www.nicd.ac.za/increase-in-pertussis-cases-in-south-africa-21-sept-2022/
3. Mooi FR, Van Der Maas NA, De Melker HE. Pertussis resurgence: Waning immunity and pathogen adaptation–two sides of the same coin. Epidemiol Infect 2014;142(4):685-694.
4. NICD. Pertussis frequently asked questions. 2017; https://www.nicd.ac.za/assets/files/ Pertussis%20FAQ_final_20170111_%20corrected%20date%20on%20bottom_30Jan2017.pdf
5. Bouguerra H, Hechaichi A, Atawa L, et al. Epidemiology of pertussis in Tunisia: Results of five years 2013-2017. Eur J Public Health 2019;29 (Supplement 4).
6. NICD. Update on increase in pertussis cases in South Africa, November 2018. https://www.nicd. ac.za/wp-content/uploads/2018/11/Update-on-increase-in-pertussis-cases-in-South-Africa.pdf 7. Kavitha T, Samprathi M, Jayashree M, Gautam V, Sangal L. Clinical profile of critical pertussis in
children at a pediatric intensive care unit in Northern India. Indian Pediatrics 2020;57:228-231. 8. Birru F, Al-Hinai Z, Thani SA, Al-Mukhaini K, Al-Zakwani I, Al-Abdwan R. Critical pertussis: A multi-centric analysis of risk factors and outcomes in Oman. Int J Infect Dis 2021;107:53-58.
9. Winter K, Zipprich J, Harriman K, et al. Risk factors associated with infant deaths from pertussis: A case-control study. Clin Infect Dis 2015;61(7):1099-1106.
10. Shi T, Wang L, Du S, et al. Mortality risk factors among hospitalized children with severe pertussis. BMC Infect Dis 2021;21(1) 1057.
11. Berger JT, Carcillo J, Shanley TP, et al. Critical pertussis illness in children, a multicenter prospective cohort study. Pediatric Crit Care Med 2013;14(4):356-365.
12. Paddock CD, Sanden GN, Cherry JD, et al. Pathology and pathogenesis of fatal Bordetella pertussis infection in infants. Clin Infect Dis 2008;47(3):328-338.
13. Nieves D, Bradley JS, Gargas J, et al. Exchange blood transfusion in the management of severe pertussis in young infants. Pediatric Infect Dis J 2013;32(6):698-699.
14. Kuperman A, Hoffmann Y, Glikman D, Dabbah H, Zonis Z. Severe pertussis and hyperleukocytosis: Is it time to change for exchange? Transfusion 2014;54(6):1630-1633.
15. Rowlands HE, Goldman AP, Harrington K, et al. Impact of rapid leukodepletion on the outcome of severe clinical pertussis in young infants. Pediatrics 2010;126(4):816-827.
16. Cherry JD, Wendorf K, Bregman B, et al. An observational study of severe pertussis in 100 infants≤120 days of age. Pediatric Infect Dis J 2018;37(3):202-205.
17. Hallbauer U, Joubert G, Goosen Y. Pertussis in children in Bloemfontein, South Africa: A 7-year retrospective review. S Afr Med J 2016;106(10):1042-1046.
18. World Health Organization. Surveillance standards for vaccine-preventable diseases, 2nd ed. 2018. https://www.who.int/publications/i/item/surveillance-sta1ndards-for-vaccine-preventable- diseases-2nd-edition
19. Martini H, Detemmerman L, Soetens O, Yusuf E, Piérard E. Improving specificity of Bordetella pertussis detection using a four-target real-time PCR. PLoS One 2017;12(4):e0175587.
20. Ostermann M, Bellomo R, Burdmann EA, et al. Controversies in acute kidney injury: Conclusions from a kidney disease: Improving Global Outcomes (KDIGO) Conference. Kidney Int 2020;98(2):294-309.
21. Squires J, McKiernan P, Squires R. Pediatric Organ Dysfunction Information Update Mandate (PODIUM) Collaborative. Acute liver dysfunction criteria in critically ill children: The PODIUM Consensus Conference. Pediatrics 2022;149:S59.
22. Weiss SL, Peters MJ, Alhazzani W, et al. Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children. Intensive Care Med 2020;46:10-67.
23. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care–associated infection and criteria for specific types of infections in the acute care setting. Am J infect Control 2008;36(5):309-332.
24. Consolaro A, Giancane G, Schiappapietra B, Davì S, et al. Clinical outcome measures in juvenile idiopathic arthritis. Pediatric Rheumatol 2016;14:1-8.
25. Straney L, Schibler S, Ganeshalingham A, et al. Burden and outcomes of severe pertussis infection in critically ill infants. Pediatric Crit Care Med 2016;17(8):735-742.
26. Borgi A, Menif K, Belhadj S, et al. Predictors of mortality in mechanically ventilated critical pertussis in a low-income country. Mediterranean J Hematol Infect Dis 2014:6(1).
27. Munoz FM, Bond NH, Maccato M, et al. Safety and immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants: A randomized clinical trial. JAMA 2014;311(17):1760-1769.
28. Abu-RayaB, Bettinger JA, Vanderkooi OG, et al. Burden of children hospitalized with pertussis in Canada in the acellular pertussis vaccine era, 1999–2015. J Pediatric Infect Dis Soc 2020;9(2):118-127.
29. Anh Tuan T, Xoay TD, Thuy PTB, Ouellette Y. Cerebral spinal fluid positive pertussis encephalopathy in infants. SAGE Open Medical Case Reports 2021;9:2050313X211052446.
30. Madden I, Roumenina LT, Langlois-Meurinne H, et al. Hemolytic uremic syndrome associated
with Bordetella pertussis infection in a 2-month-old infant carrying a pathogenic variant in
complement factor H. Pediatric Nephrol 2019;34:533-537.
31. Saida K, Ogura M, Kano Y, et al. Treatment of hemolytic uremic syndrome related to Bordetella
pertussis infection—is plasma exchange or eculizumab use necessary? BMC Nephrol 2018;19:1-4. 32. Chaturvedi S, Licht C, Langlois V. Hemolytic uremic syndrome caused by Bordetella pertussis
infection. Pediatric Nephrol 2010;25:1361-1364.
33. Bellettini CV, de Oliveira AW, Tusset C, et al. Clinical, laboratorial and radiographic predictors of
Bordetella pertussis infection. Revista Paulista de Pediatria 2014;32:292-298.
34. Coquaz-Garoudet M, Ploin D, Pouyau R, et al. Malignant pertussis in infants: factors associated
with mortality in a multicenter cohort study. Ann Intensive Care 2021;11(1):70.
35. Wu X-Y. The role of hyperleukocytosis in predicting the severity of pertussis. 2020. https://doi.
org/10.21203/rs.3.rs-132275/v1
36. Altunaiji SM, Kukuruzovic R, Curtis, N, Massie J. Cochrane Review: Antibiotics for whooping cough (pertussis). Evidence-based child health: A Cochrane Rev J 2012;7(3):93-956.
37. Mir-Cros A, Codina G, Martín-Gómez MT, et al. Emergence of Bordetella holmesii as a causative agent of whooping cough, Barcelona, Spain. Emerging Infect Dis 2017;23(11):1856.
38. de Greeff SC, van Buul LW, Westerhof A, et al. Pertussis in infancy and the association with respiratory and cognitive disorders at toddler age. Vaccine 2011;29(46):8275-8278.
39. Berger JT, Villalobos ME, Clark AE, et al. Cognitive development one year after infantile critical pertussis. Pediatr Crit Care Med 2018;19(2):89-97.